1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

2024 Activity indicators

  • 4 public competitive projects led: ISCIII 
  • 2 private projects led 
  • 152 clinical studies 
  • 46 publications 
  • IF: 349.30 
  • Publications in Q1: 35 (76%) 
  • Publications in D1: 12 (26%) 
  • 1 thesis 
  • 5 awards 
  • Evaluator from national and international institutions: 3 researchers 
  • Member of editorial committee: 1 PI 
  • 1 visitor hosted and 6 months stay: 
    • Universidad Politécnica de Madrid 
  • 4 months stay in a foreign center: 
  • Memorial Sloan Kettering Cancer Center (USA)
  • Impact on society: 14 hematologists from Mexico hosted (Preceptorship Visit)

Milestones

  1. Award of a new public project of the AES24 (ISCIII) of Dr. García Gutiérrez (PI24/00861) that reinforces the four already initiated in recent years: Dr. Luna (PI23/01924), Dr. García Gutiérrez (PI21/00877), intensification contract AES of Dr. García Gutiérrez (INT23/00058) and FORTALECE - FAR IRYCIS (FORT23/00046).
  2. Implementation of 6 clinical trials related to CAR-T therapy in benign diseases as well as in non-hematological neoplasms.
  3. Pérez L, de Paz R, Díaz R, Montero LFC, Payer ÁR, Sierra M, Marín FF, López RP, Cirici BX, Steegmann JL, Gómez MT, Martínez J, García V. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study. Ann Hematol. 2024;103(10): 4045 - 4055. DOI:10.1007/s00277-024-05662-7.
  4. Recognition as one of the best abstracts of the National Congress of the Spanish Society of Hematology, in plenary session of the congress, selecting the 5 best from more than 1000 submitted. 
  5. Mateos MV, Martínez J, Rodriguez P, González V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos R, Rosiñol L, Alvarez MA, Bargay J, Gonzalez AP, Alegre A, Escalante F, Iñigo MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, López J, Reinoso M, García A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San JF, Spanish Myeloma Group Curative Strategy for High-Risk Smoldering Myeloma: Carfi lzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024;42(27): 3247 - 3256. DOI:10.1200/JCO.23.02771. FI: 24; Altmetrics 36.

Networks and alliances